GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » PB Ratio

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) PB Ratio : 3.12 (As of Jun. 18, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-06-18), Great Novel Therapeutics Biotech & Medicals's share price is NT$48.35. Great Novel Therapeutics Biotech & Medicals's Book Value per Share for the quarter that ended in Dec. 2023 was NT$15.50. Hence, Great Novel Therapeutics Biotech & Medicals's PB Ratio of today is 3.12.

Good Sign:

Great Novel Therapeutics Biotech & Medicals stock PB Ratio (=3.12) is close to 3-year low of 2.89

The historical rank and industry rank for Great Novel Therapeutics Biotech & Medicals's PB Ratio or its related term are showing as below:

ROCO:7427' s PB Ratio Range Over the Past 10 Years
Min: 2.89   Med: 5.32   Max: 11.64
Current: 3.12

During the past 6 years, Great Novel Therapeutics Biotech & Medicals's highest PB Ratio was 11.64. The lowest was 2.89. And the median was 5.32.

ROCO:7427's PB Ratio is ranked worse than
60.23% of 1300 companies
in the Biotechnology industry
Industry Median: 2.4 vs ROCO:7427: 3.12

During the past 12 months, Great Novel Therapeutics Biotech & Medicals's average Book Value Per Share Growth Rate was 43.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 33.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 27.20% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Great Novel Therapeutics Biotech & Medicals was 36.90% per year. The lowest was 14.10% per year. And the median was 33.90% per year.

Back to Basics: PB Ratio


Great Novel Therapeutics Biotech & Medicals PB Ratio Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals PB Ratio Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - - 4.46 5.06 4.15

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.46 4.23 5.06 5.90 4.15

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's PB Ratio

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Great Novel Therapeutics Biotech & Medicals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's PB Ratio falls into.



Great Novel Therapeutics Biotech & Medicals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Great Novel Therapeutics Biotech & Medicals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=48.35/15.498
=3.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Great Novel Therapeutics Biotech & Medicals PB Ratio Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines